A San Francisco startup with Neuralink ties has started testing its brain implant to detect and treat cancer in humans. The coin-sized device is designed to sense tumor electrical signals and deliver mild stimulation to prevent growth.

Matthew MacDougall, a head neurosurgeon at Neuralink, now advises the company while Rory Murphy, an investigator in one of Neuralink’s trials, will be involved in future tests. The implant's unique design promises more convenience than current wearable devices like Optune, which requires scalp patches.

Coherence aims to treat glioblastoma, a high-risk cancer that most patients survive for less than two years after diagnosis. Their device could offer continuous monitoring and personalized therapy, alerting doctors of potential rapid growth before an MRI can catch it.

The company plans to begin trials next year with permanent implantation in glioblastoma patients, marking a significant step towards integrating tech into our most vital organ for health management.